Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
BRCA2-related cancer predisposition - Clinical Profile, Genes & Research | Kisho | Kisho
Rare Disease
BRCA2-related cancer predisposition
MONDO:0700269
Overview
Hereditary cancer predisposition due to variation(s) in the BRCA2 gene. Germline pathogenic or likely pathogenic variants in the BRCA2 gene confer an autosomal dominant predisposition to hereditary breast and ovarian cancer. Tumor formation at other sites, including pancreatic and prostate cancer, have been described.
ResearchLimited published research (6 articles)
Diagnosis
Biomarker and diagnostic research for BRCA2-related cancer predisposition has been reported in the published literature.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
No clinical trials have been registered for BRCA2-related cancer predisposition.
6 publications have been identified in PubMed for BRCA2-related cancer predisposition. Research spans Review / Meta-Analysis (33%), Epidemiology / Natural History (33%), and Diagnostic / Biomarker (17%).
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?
FAQ
Frequently Asked Questions
Common questions about BRCA2-related cancer predisposition
BRCA2-related cancer predisposition is a hereditary condition that increases the risk of developing cancer caused by changes in the BRCA2 gene. These changes are inherited and can raise the risk for cancers such as breast and ovarian cancer. Additionally, tumors may form in other areas like the pancreas and prostate.
Information about symptoms is currently limited for this condition.
This condition is caused by germline pathogenic or likely pathogenic variants in the BRCA2 gene. These genetic changes are inherited in an autosomal dominant manner, which means that a change in just one copy of the gene can increase the risk of developing cancer.
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.
